Liminatus Pharma (LIMN) Stock Price, News & Analysis

Company Overview

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Key Stats

• Today's Range: $16.50 to $22.71
• 50-Day Range: N/A
• 52-Week Range: $4.40 to $33.66
• Volume: 196,180 shs
• Average Volume: 358,298 shs
• Market Capitalization: $431.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LIMN Stock Analysis - Frequently Asked Questions

How have LIMN shares performed this year?

Liminatus Pharma's stock was trading at $23.98 on January 1st, 2025. Since then, LIMN stock has decreased by 30.8% and is now trading at $16.60.
View the best growth stocks for 2025 here.

How do I buy shares of Liminatus Pharma?

Shares of LIMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIMN
• Previous Symbol: NASDAQ:LIMN
• CIK: 1971387
• Web: liminatuspharma.com
• Phone: (213) 273-5453
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,010,000
• Free Float: N/A
• Market Cap: $623.72 million
• Optionable: N/A
• Beta: N/A